Category: Blog

On behalf of 65 professors, Prof. Michael Carrier filed a Brief of Amici Curiae 65 Professors of Law, Business, Economics, and Sports Management that supported the student-athletes in NCAA v. Alston. The brief has three main points. First, the Petitioners (the NCAA and athletics conferences) seek to unwind a century of antitrust law by obtaining … Continue reading On behalf of 65 professors, Prof. Michael Carrier co-authors Supreme Court brief…

Standards, common platforms allowing products to work together, are ubiquitous in our economy. But imagine that a company: (1) has a patent needed to use a standard, (2) promises to license the patent on reasonable terms, and then (3) says it was just kidding as it seeks to block the product or charge an exorbitant … Continue reading Prof. Michael Carrier published “Rescuing Antitrust’s Role in Patent Holdup” in the University of Pennsylvania Law Review Online…

Competition is the key to low prices in the pharmaceutical industry. For decades, Americans have benefited from affordable generic versions of brand-name drugs. But now, we stand poised on the wave of a revolution. Biologics, which include lifesaving cancer-treating drugs, can cost hundreds of thousands of dollars per year and are forecast to be the … Continue reading Prof. Michael Carrier published “Don’t Die! How Biosimilar Disparagement Violates Antitrust Law” in the Northwestern University Law Review Online…

Prof. Michael Carrier presented a lecture on “Three Challenges for Pharmaceutical Antitrust” to Harvard’s Program on Regulation, Therapeutics, and Law.

Prof. Michael Carrier participated in the panel “New Opportunities for American Leadership in Standards and IP Policy” sponsored by ACT / The App Association